Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results

Cancer Treat Rev. 1991 Mar:18 Suppl A:37-46. doi: 10.1016/0305-7372(91)90023-s.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Altretamine / administration & dosage
  • Altretamine / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Female
  • Follow-Up Studies
  • Humans
  • Neoplasm Staging
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / pathology

Substances

  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
  • Altretamine

Supplementary concepts

  • CISCA protocol
  • HAC protocol